Skip to main content

181 - References

References

178 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

  1. Schimmelbusch WH, et al. The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia. Br J Psychiatry 1971; 118:429–436.
  2. Waitzkin L. A survey for unknown diabetics in a mental hospital. I. Men under age fifty. Diabetes 1966; 15:97–104.
  3. Kasanin J. The blood sugar curve in mental disease. II. The schizophrenia (dementia praecox) groups. Arch Neurol Psychiatry 1926; 16:414–419.
  4. Braceland FJ, et al. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945; 102:108–110.
  5. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004; 47:S64–S66.
  6. Glechner A, et al. Effects of lifestyle changes on adults with prediabetes: a systematic review and meta-­analysis. Prim Care Diabetes 2018; 12:393–408.
  7. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline [NG28]; 2015 (last updated June 2022, last checked March 2024); https://www.nice.org.uk/guidance/ng28.
  8. Haddad PM. Antipsychotics and diabetes: review of non-­prospective data. Br J Psychiatry Suppl 2004; 47:S80–S86.
  9. Bushe C, et al. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry 2004; 184:S87–S93.
  10. Hirigo AT, et al. The magnitude of undiagnosed diabetes and hypertension among adult psychiatric patients receiving antipsychotic treatment. Diabetol Metab Syndr 2020; 12:79.
  11. Poulos J, et  al. Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses. Psychol Med 2023; 53:7677–7684.
  12. Lindekilde N, et al. Risk of developing type 2 diabetes in individuals with a psychiatric disorder: a nationwide register-­based cohort study. Diabetes Care 2022; 45:724–733.
  13. Taylor D, et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185:152–156.
  14. Gianfrancesco F, et al. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry 2006; 18:9–17.
  15. Buchholz S, et al. Atypical antipsychotic-­induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 2008; 38:602–606.
  16. Farino ZJ, et  al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol Psychiatry 2020; 25:2070–2085.
  17. Wei H, et  al. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology 2020; 113:104551.
  18. Teff KL, et al. Antipsychotic-­induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013; 62:3232–3240.
  19. Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatr 1964; 5:181.
  20. Lindenmayer JP, et al. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 Suppl 23:30–38.
  21. Keskiner A, et al. Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics 1973; 14:176–181.
  22. Tollefson G, et al. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry 1983; 44:347–348.
  23. Lindenmayer JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290–296.
  24. Carlson C, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol 2006; 16:366–375.
  25. Ostbye T, et  al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2005; 14:407–415.
  26. Smith M, et al. First-­ v. second-­generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-­analysis. Br J Psychiatry 2008; 192:406–411.
  27. Mir S, et al. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16:63–74.
  28. Lund BC, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-­based approach. Arch Gen Psychiatry 2001; 58:1172–1176.
  29. Sernyak MJ, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561–566.
  30. Gianfrancesco FD, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63:920–930.
  31. Guo JJ, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-­based, case-­control study. J Clin Psychiatry 2006; 67:1055–1061.
  32. Wang PS, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002; 22:236–243.
  33. Sumiyoshi T, et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine [Letter]. J Clin Psychopharmacol 2004; 24:345–348.
  34. Henderson DC, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-­year naturalistic study. Am J Psychiatry 2000; 157:975–981.
  35. Koller E, et al. Clozapine-­associated diabetes. Am J Med 2001; 111:716–723.
  36. Sumiyoshi T, et al. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs [Letter]. J Clin Psychopharmacol 2004; 24:452–454.

Schizophrenia and related psychoses CHAPTER 1 37. Zhang R, et al. The prevalence and clinical-­demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine. Hum Psychopharmacol 2011; 26:392–396. 38. Melkersson KI, et al. Different influences of classical antipsychotics and clozapine on glucose-­insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60:783–791. 39. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14:115–119. 40. Newcomer JW, et  al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337–345. 41. Lamberti JS, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-­demographic correlates. J Clin Psychiatry 2005; 66:900–906. 42. Miyakoshi T, et al. Risk factors for abnormal glucose metabolism during antipsychotic treatment: a prospective cohort study. J Psychiatr Res 2023; 168:149–156. 43. Wirshing DA, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778–783. 44. Engl J, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005; 10:1089–1096. 45. Vestri HS, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007; 32:765–772. 46. Koro CE, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-­control study. BMJ 2002; 325:243. 47. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone-­ and olanzapine-­treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425–433. 48. Gianfrancesco F, et al. Antipsychotic-­induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23:328–335. 49. Leslie DL, et  al. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709–1711. 50. Duncan E, et  al. Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. Int Clin Psychopharmacol 2007; 22:1–11. 51. Meyer JM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008; 101:273–286. 52. Ebenbichler CF, et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003; 64:1436–1439. 53. Mallya A, et al. Resolution of hyperglycemia on risperidone discontinuation: a case report. J Clin Psychiatry 2002; 63:453–454. 54. Wirshing DA, et al. Risperidone-­associated new-­onset diabetes. Biol Psychiatry 2001; 50:148–149. 55. Croarkin PE, et al. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41:369–370. 56. Koller EA, et al. Risperidone-­associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23:735–744. 57. Lambert BL, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006; 164:672–681. 58. Henderson DC. Atypical antipsychotic-­induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77–89. 59. Koller EA, et al. A survey of reports of quetiapine-­associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65:857–863. 60. Nanasawa H, et al. Development of diabetes mellitus associated with quetiapine: a case series. Medicine (Baltimore) 2017; 96:e5900. 61. Ulcickas Yood M, et al. Association between second-­generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry 2011; 11:197. 62. Correll CU, et al. Cardiovascular and cerebrovascular risk factors and events associated with second-­generation antipsychotic compared to antidepressant use in a non-­elderly adult sample: results from a claims-­based inception cohort study. World Psychiatry 2015; 14:56–63. 63. Bushe C, et al. Comparison of metabolic and prolactin variables from a six-­month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol 2010; 24:1001–1009. 64. Guo Z, et  al. A real-­world data analysis of dose effect of second-­generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1326–1332. 65. Vanelle JM, et al. A double-­blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006; 21:523–530. 66. Toprak O, et al. New-­onset type II diabetes mellitus, hyperosmolar non-­ketotic coma, rhabdomyolysis and acute renal failure in a patient treated with sulpiride. Nephrol Dial Transplant 2005; 20:662–663. 67. Keck PE, Jr., et al. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Invest Drugs 2003; 12:655–662. 68. Pigott TA, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-­controlled 26-­week study. J Clin Psychiatry 2003; 64:1048–1056. 69. van WR, et al. Major changes in glucose metabolism, including new-­onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69:472–479. 70. Baker RA, et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009; 42:11–31. 71. Simpson GM, et al. Randomized, controlled, double-­blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:1837–1847. 72. Sacher J, et  al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008; 33:1633–1641.

180 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 73. De Hert M, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33:823–­830. 74. Church CO, et al. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005; 22:1440–1443. 75. Reddymasu S, et al. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. J Pancreas 2006; 7:303–305. 76. Campanella LM, et al. Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole. Ann Emerg Med 2009; 53:264–266. 77. Kessing LV, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197:266–271. 78. Vancampfort D, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-­analysis. World Psychiatry 2016; 15:166–174. 79. McEvoy JP, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-­week, open-­label study. J Clin Psychiatry, 2013; 74:170–179. 80. Stahl SM, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-­month, open-­label, extension study. J Clin Psychiatry 2013; 74:507–515. 81. McIntyre RS, et al. Asenapine for long-­term treatment of bipolar disorder: a double-­blind 40-­week extension study. J Affect Disord 2010; 126:358–365. 82. McIntyre RS, et al. Asenapine versus olanzapine in acute mania: a double-­blind extension study. Bipolar Disord 2009; 11:815–826. 83. Garnock-­Jones KP. Brexpiprazole: a review in schizophrenia. CNS Drugs 2016; 30:335–342. 84. Newcomer JW, et al. Changes in metabolic parameters and body weight in patients with major depressive disorder treated with adjunctive brexpiprazole: pooled analysis of phase 3 clinical studies. J Clin Psychiatry 2019; 80:18m12680. 85. Lao KS, et al. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-­analysis of randomized controlled trials. CNS Drugs 2016; 30:1043–1054. 86. Earley W, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studies. J Affect Disord 2017; 215:205–212. 87. Barabássy Á, et al. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies. Neuropsychiatr Dis Treat 2021; 17:957–970. 88. Cernea S, et al. Pharmacological management of glucose dysregulation in patients treated with second-­generation antipsychotics. Drugs 2020; 80:1763–1781. 89. Correll CU, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2020; 77:349–358. 90. Hammerman A, et al. Antipsychotics and diabetes: an age-­related association. Ann Pharmacother 2008; 42:1316–1322. 91. Galling B, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-­analysis. JAMA Psychiatry 2016; 73:247–259. 92. Albert SG, et al. Atypical antipsychotics and the risk of diabetes in an elderly population in long-­term care: a retrospective nursing home chart review study. J Am Med Dir Assoc 2009; 10:115–119. 93. De Hert M, et al. Typical and atypical antipsychotics differentially affect long-­term incidence rates of the metabolic syndrome in first-­ episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101:295–303. 94. Saddichha S, et al. Metabolic syndrome in first episode schizophrenia: a randomized double-­blind controlled, short-­term prospective study. Schizophr Res 2008; 101:266–272. 95. Saddichha S, et al. Diabetes and schizophrenia –­ effect of disease or drug? Results from a randomized, double-­blind, controlled prospective study in first-­episode schizophrenia. Acta Psychiatr Scand 2008; 117:342–347. 96. Reaven GM, et al. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009; 43:997–1002. 97. Heald AH, et al. Changes in metabolic parameters in patients with severe mental illness over a 10-­year period: a retrospective cohort study. Aust N Z J Psychiatry 2017; 51:75–82. 98. Mokdad AH, et al. The continuing increase of diabetes in the US. Diabetes Care 2001; 24:412. 99. Mokdad AH, et al. Diabetes trends in the US: 1990–1998. Diabetes Care 2000; 23:1278–1283. 100. Beckman JA, et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570–2581. 101. Henderson DC, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-­year naturalistic study. J Clin Psychiatry 2005; 66:1116–1121. 102. Lamberti JS, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163:1273–1276. 103. Goff DC, et al. A comparison of ten-­year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80:45–53. 104. Haupt DW, et al. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl 27:15–26. 105. Cohn TA, et al. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492–501. 106. De Hert M, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199:99–105. 107. Barnes TR, et al. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118:26–33. 108. Barnes TR, et al. Screening for the metabolic side effects of antipsychotic medication: findings of a 6-­year quality improvement programme in the UK. BMJ Open 2015; 5:e007633. 109. Crawford MJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-­sectional study. Br J Psychiatry 2014; 205:473–477. 110. Morrato EH, et al. Metabolic screening after the ADA’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009; 32:1037–1042.

Schizophrenia and related psychoses CHAPTER 1 111. De Hert M, et al. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 2006; 21:224–226. 112. Pillinger T, et al. Impaired glucose homeostasis in first-­episode schizophrenia: a systematic review and meta-­analysis. JAMA Psychiatry 2017; 74:261–269. 113. Marder SR, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349. 114. National Institute for Health and Care Excellence. Prescribing information: monitoring. Psychosis and schizophrenia: what monitoring is required? (Last revised October 2024; last checked January 2025); https://cks.nice.org.uk/topics/psychosis-­schizophrenia/prescribing-­ information. 115. Stroup TS, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-­year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013; 146:190–195. 116. Chen Y, et al. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-­month, prospective, open-­label study. J Psychopharmacol 2012; 26:1201–1210. 117. Wang YH, et al. Lurasidone successfully reversed clozapine-­induced type 2 diabetes mellitus and hypertriglyceridemia in a patient with schizophrenia. Am J Ther 2023; 30:e490–e491. 118. Smith RC, et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-­blind study. Schizophr Res 2013; 143:18–24. 119. Larsen JR, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-­ or olanzapine-­treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017; 74:719–728. 120. Patoulias D, et al. Effect of glucagon-­like peptide-­1 receptor agonists on cardio-­metabolic risk factors among obese/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-­analysis of randomized controlled trials. Biomedicines 2023; 11:669. 121. Noda K, et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetol Int 2022; 13:693–697.

No comments to display

Back to top